| Ytd | -7.00% | |
| 1y | 113.57% |
| Open | 39.18 | Prev Close | 38.29 | Low | 38.98 | High | 39.94 | Mkt Cap | 737.12M |
| Vol | 44.44K | Avg Vol | 394.00K | EPS | 19.29 | P/E | 2.07 | Forward P/E | 19.49 |
| Beta | 0.95 | Short Ratio | 1.69 | Inst. Own | 68.01% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-04 | 50-d Avg | 31.20 | 200-d Avg | 34.01 | 1yr Est | 31.33 |
RIGL News
Dr. Hannah has decades of oncology drug development experience and has served on Rigel's Board of Di
Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL), a commercial stage biotechnology company focused on hemat
HC Wainwright & Co. analyst Joseph Pantginis reiterates Rigel Pharmaceuticals (NASDAQ:RIGL) w
HC Wainwright & Co. analyst Joseph Pantginis reiterates Rigel Pharmaceuticals (NASDAQ:RIGL) w
HC Wainwright & Co. analyst Joseph Pantginis reiterates Rigel Pharmaceuticals (NASDAQ:RIGL) w
Citigroup analyst Yigal Nochomovitz maintains Rigel Pharmaceuticals (NASDAQ:RIGL) with a Buy and
Arvinas Inc (NASDAQ:ARVN) reported Q1 losses of 90 cents/share, missed analyst estimates. Rigel Phar
Rigel Pharmaceuticals stock jumps after signing a VEPPANU licensing deal with Arvinas and Pfizer fol
Arvinas, Inc. (NASDAQ:ARVN), a biotechnology company creating a new class of drugs based on targeted
Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL), a commercial stage biotechnology company focused on hemat
Citigroup analyst Yigal Nochomovitz maintains Rigel Pharmaceuticals (NASDAQ:RIGL) with a Buy and
Rigel Pharmaceuticals (NASDAQ:RIGL) affirms FY2026 sales outlook from $275.000 million-$290.000 mill
Rigel Pharmaceuticals (NASDAQ:RIGL) reported quarterly earnings of $0.44 per share which missed the
Termination of a Material Definitive Agreement.On April 16, 2026, Rigel Pharmaceuticals, Inc. ("
https://www.fda.gov/drugs/fda-adverse-event-monitoring-system-aems/october-december-2025-new-safety-
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hema
U.S. stocks up on Wednesday with NASDAQ gaining 0.85%. ISM services PMI rose to 56.1. VCI Global Ltd
Rigel Pharmaceuticals (NASDAQ:RIGL) affirms FY2026 sales outlook from $275.000 million-$290.000 mill
Rigel Pharmaceuticals (NASDAQ:RIGL) reported quarterly earnings of $1.12 per share which missed the
Preliminary fourth quarter 2025 total revenue of approximately $69.8 million, including net product
R289 continues to be generally well tolerated and at doses of ≥500 mg QD preliminary efficacy was ob
Olutasidenib continued to demonstrate durable efficacy and a manageable safety profile in a broad ra
Jefferies analyst Eun Yang upgrades Rigel Pharmaceuticals (NASDAQ:RIGL) from Hold to Buy and rais
Cantor Fitzgerald analyst Kristen Kluska maintains Rigel Pharmaceuticals (NASDAQ:RIGL) with a Neu
Rigel Pharmaceuticals (NASDAQ:RIGL) raises FY2025 sales outlook from $210.000 million-$220.000 milli
Rigel Pharmaceuticals (NASDAQ:RIGL) reported quarterly earnings of $1.46 per share which beat the an
Dose expansion phase will determine the recommended Phase 2 dose of R289 for patients with transfusi
HC Wainwright & Co. analyst Joseph Pantginis reiterates Rigel Pharmaceuticals (NASDAQ:RIGL) w
Cantor Fitzgerald analyst Kristen Kluska maintains Rigel Pharmaceuticals (NASDAQ:RIGL) with a Neu
Rigel Pharmaceuticals (NASDAQ:RIGL) reported quarterly earnings of $3.28 per share which beat the an
Rigel Pharmaceuticals (NASDAQ:RIGL) raises FY2025 sales outlook from $200.000 million-$210.000 milli
Final data from the GAVRETO® (pralsetinib) Phase 1/2 ARROW study in RET fusion-positive NSCLC and ot
Cantor Fitzgerald analyst Kristen Kluska maintains Rigel Pharmaceuticals (NASDAQ:RIGL) with a Neu